This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 25, 2021 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.
2
Harmony's Strategy for Growth
Optimize
Expand
Acquire
Clinical
WAKIX ®
New
Utility of
Performance
Assets
WAKIX
3
Q3 2021 WAKIX Revenue Performance
Continued Growth with Q3 Revenue of $80.7M
$80.7
$73.8
$56.3
$59.7
$45.6
$38.0
$19.8
$6.0
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
2019
2020
2020
2020
2020
2021
2021
2021
3Q21
3Q21
3Q20
2Q21
3Q21
vs.
vs.
2Q21
3Q20
$45.6
$73.8
$80.7
9.4%
77%
Strong Revenue Growth in Q3 2021
9.4% growth Q3 2021 vs. Q2 2021
77% growth Q3 2021 vs. Q3 2020
Continued sequential quarter over quarter growth from launch
WAKIX Net Revenue ($m)
4
Driving Growth Through Our Launch For WAKIX Q3 2021 Performance
Increased
Access to HCPs
~3,500 Average # of
WAKIX Patients
Patient Outreach
Programs & Support
~40%
Of 8,000 unique HCPs have
prescribed WAKIX since launch
Healthcare Professional
Educational Initiatives
~80% U.S. Covered Lives With Formulary Access
Managed Care
Education & Outreach
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Harmony Biosciences Holdings Inc. published this content on 09 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 November 2021 13:13:06 UTC.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.
HARMONY BIOSCIENCES HOLDINGS, INC. 
